Durvalumab Biosimilar, Endotoxin 0.05 EU/mg | Catalog C025P.05

Durvalumab Biosimilar, Endotoxin 0.05 EU/mg. The research grade Durvalumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

Product Specifications

Catalog No.	C025P.05
Product Name	Durvalumab Biosimilar, Endotoxin 0.05 EU/mg
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Programmed death-ligand 1, PD-L1, cluster of differentiation 274, CD274, B7 homolog 1, B7-H1
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	Produced in the durvalumab biosimilar CHO stable cell line.
Specificity	Specifically binds to human programmed cell death ligand 1 (PD-L1), blocking its interaction with PD-1 and B7-1.

Properties & Storage

Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays.
Formulation	0.2 µM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	< 0.05 EU per 1 mg of protein by LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	Shipped with ice pack. Store immediately at recommended temperature.
Storage	12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles.

Background & Description

Durvalumab Biosimilar uses the same protein sequences as the therapeutic antibody durvalumab. PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD1 (CD279, programmed cell death 1). Durvalumab is a humanized monoclonal antibody directed against human PD-L1 (B7-H1 or CD274), completely blocking binding to PD-1 and CD80, with IC_{50}s of 0.1 and 0.04 nM, respectively.

Durvalumab is an anticancer antibody promoting antitumor responses mediated by immune cells, increasing T-cell activation, and enhancing tumor cell ablation without mediating antibody-dependent cell-mediated cytotoxicity (ADCC).